Renalytix plc announced that O. James Sterling will step down from his role as Chief Financial Officer of the company as of 24 May 2024 and will remain at the company until 10 June 2024. The Board has appointed Joel R. Jung as Interim Chief Financial Officer, effective immediately while a handover period takes place. Prior to his appointment as the Company?s Interim Chief Financial Officer, Mr. Jung, age 66, served as Chief Financial Officer at Minerva Surgical Inc. from July 2020 to February 2024.

Mr. Jung served as a financial consultant to several life sciences companies from October 2018 to July 2020. From October 2018 to June 2019, Mr. Jung held various positions at uBiome Inc., including as Chief Financial Officer from March 2019 to June 2019. uBiome filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in September 2019, which was converted into a Chapter 7 case in October 2019.

Prior to that, Mr. Jung served as the Chief Financial Officer for four companies including Counsyl Inc. (acquired by Myriad Genetics Inc.) from July 2016 to September 2018, Bionano Genomics Inc. from February 2014 to June 2016, AgraQuest Inc. (acquired by Bayer CropScience) from February 2010 to December 2012, and Celera Corporation from June 2008 to April 2009. He also served as Vice President of Finance with Bayer CropScience from December 2012 to June 2013, Applera Corporation from June 2006 to June 2008, and Chiron Corporation from September 1999 to April 2003, and Vice President and Treasurer of Chiron Corporation from April 2003 to July 2006. Mr. Jung holds a B.S. Degree in Aeronautical Engineering from Purdue University and an M.B.A. from the Haas School of Business at the University of California, Berkeley.